PPM1H CRISPR Activation Plasmid (h): sc-412800-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- PPM1H CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- PPM1H CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by PPM1H CRISPR Activation Plasmid (h) and PPM1H CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the PPM1H transcriptional start site. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PPM1H CRISPR Activation Plasmid (h) | sc-412800-ACT | 20 µg | $397.00 |
PPM1H encodes a PP2C-family Mg2+/Mn2+-dependent serine/threonine protein phosphatase that counterbalances kinase signaling by dephosphorylating regulatory substrates and modulating phosphorylation-dependent protein stability and activity. Through its role in phospho-signaling homeostasis, PPM1H contributes to control of cellular growth, stress responses, and proteostasis-related processes, including pathways influenced by ubiquitin-mediated regulation. Altered phosphatase activity and disrupted kinase–phosphatase balance are frequently implicated in oncogenic signaling and other pathophysiological states, making PPM1H a useful node for mechanistic studies of signal termination and pathway rewiring.
PPM1H CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous PPM1H expression without altering the underlying DNA sequence.
PPM1H CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the PPM1H locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the PPM1H transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous PPM1H expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native PPM1H locus and enabling the study of PPM1H-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of PPM1H pathway restoration in tumor cells with silenced or reduced PPM1H expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.